Cd3d-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Cd3d-KO 基因敲除小鼠

产品编号

S-KO-01413

品系全称

C57BL/6JCya-Cd3dem1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-12500-Cd3d-B6J-VA

品系状态

使用本品系发表的文献需注明: Cd3d-KO 基因敲除小鼠 mice (Strain S-KO-01413) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
CD3 antigen, delta polypeptide
基因别称
T3d
染色体号
Chr 9 (Mouse)
转录本 ID
NCBI: NM_013487 | Ensembl: ENSMUST00000034602
修饰方式
全身性基因敲除
靶向范围
Exon 2~5
敲除长度
~1.6 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:88331Homozygotes for targeted null mutations exhibit impaired early thymic development, small numbers of peripheral TCR-alpha/beta+ T cells, and failure of T lymphocyte transition from double-positive to single-positive developmental stages.
CD3D,即CD3 delta链,是T细胞受体(TCR)/CD3复合物的一部分,对T细胞的发育和信号传导至关重要。CD3D的编码基因位于人类染色体1q23上,该基因的突变会导致CD3δ严重联合免疫缺陷(CD3δ SCID),这是一种由于CD3/TCR复合物中CD3δ链缺失而导致的先天免疫缺陷病[8]。CD3D在T细胞激活过程中发挥关键作用,通过与CD3ε和CD3γ链形成复合物,介导TCR与主要组织相容性复合体(MHC)分子之间的信号传导。

CD3D在多种疾病中的作用已经得到了广泛的研究。在败血症休克的研究中,CD3D和CD247被确定为潜在的分子靶标。研究发现,败血症休克样本中CD3D和CD247的表达水平较低,而正常样本中表达水平较高。低表达的CD3D和CD247与较差的预后相关[1]。在胃癌的研究中,CD3D的高表达与较好的预后相关,且CD3D的表达与肿瘤浸润淋巴细胞(TILs)和PD-L1的表达呈正相关[2]。在糖尿病肾病(DN)的研究中,CD3D沉默通过抑制JAK/STAT通路减轻了肾脏的病理损伤,减少了炎症反应,并降低了脂质积累[3]。在膀胱癌的研究中,CD3D/CD4比值被证明是一个稳定的独立预后因素,高CD3D/CD4比值预示着更好的生存率[4]。在结肠癌的研究中,CD3D的表达与免疫检查点和免疫浸润细胞相关,且CD3D高表达的患者临床预后较好[5]。在头颈鳞状细胞癌(HNSCC)的研究中,高CD3D表达与较长的总生存期相关,且CD3D表达是HNSCC患者的独立预后因素[6]。在眼黑色素瘤(UM)的研究中,CD3D启动子的低甲基化与免疫细胞浸润相关,并支持恶性表型[7]。在类风湿性关节炎(RA)的研究中,CD3D与RA发病机制相关,并可作为RA诊断的潜在标志物,尤其是在抗瓜氨酸化蛋白抗体(ACPA)阴性患者中[9]。在急性淋巴细胞白血病(ALL)的研究中,CD3D与PRKCQ一起可以作为区分B细胞和T细胞ALL的潜在标志物[10]。

综上所述,CD3D在多种疾病中发挥重要作用,包括免疫缺陷病、癌症、糖尿病肾病、类风湿性关节炎等。CD3D的异常表达与疾病的预后相关,且CD3D的表达与免疫浸润细胞相关。因此,CD3D的研究有助于深入理解T细胞信号传导的生物学功能和疾病发生机制,为疾病的治疗和预防提供新的思路和策略。

参考文献:
1. Yang, Qian, Feng, Zhijuan, Ding, Danyang, Kang, Chunbo. . CD3D and CD247 are the molecular targets of septic shock. In Medicine, 102, e34295. doi:10.1097/MD.0000000000034295. https://pubmed.ncbi.nlm.nih.gov/37478215/
2. Yuan, Li, Xu, Jingli, Shi, Yunfu, Zhang, Bo, Yao, Qinghua. 2022. CD3D Is an Independent Prognostic Factor and Correlates With Immune Infiltration in Gastric Cancer. In Frontiers in oncology, 12, 913670. doi:10.3389/fonc.2022.913670. https://pubmed.ncbi.nlm.nih.gov/35719985/
3. Lei, Xianghong, Zou, Fangqin, Tang, Xianhu, Cheng, Shengyu, Lei, Xiangxin. . CD3D silencing alleviates diabetic nephropathy via inhibition of JAK/STAT pathway. In FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 38, e70169. doi:10.1096/fj.202401879R. https://pubmed.ncbi.nlm.nih.gov/39530557/
4. Shi, Ming-Jun, Meng, Xiang-Yu, Wu, Qiu-Ji, Zhou, Xiong-Hui. 2019. High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer. In Cancer management and research, 11, 2987-2995. doi:10.2147/CMAR.S191105. https://pubmed.ncbi.nlm.nih.gov/31114346/
5. Yang, Yi, Zang, Yiwen, Zheng, Chuang, Chen, Zongyou, Zhou, Yiming. 2020. CD3D is associated with immune checkpoints and predicts favorable clinical outcome in colon cancer. In Immunotherapy, 12, 25-35. doi:10.2217/imt-2019-0145. https://pubmed.ncbi.nlm.nih.gov/31914842/
6. Wei, Zhengyu, Shen, Yiming, Zhou, Chongchang, Deng, Hongxia, Shen, Zhisen. . CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma. In Bioengineered, 13, 13784-13800. doi:10.1080/21655979.2022.2084254. https://pubmed.ncbi.nlm.nih.gov/35712757/
7. Zhang, Chao, Wu, Shuai. . Hypomethylation of CD3D promoter induces immune cell infiltration and supports malignant phenotypes in uveal melanoma. In FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 37, e23128. doi:10.1096/fj.202300505RR. https://pubmed.ncbi.nlm.nih.gov/37651092/
8. McAuley, Grace E, Yiu, Gloria, Chang, Patrick C, Crooks, Gay M, Kohn, Donald B. 2023. Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing. In Cell, 186, 1398-1416.e23. doi:10.1016/j.cell.2023.02.027. https://pubmed.ncbi.nlm.nih.gov/36944331/
9. Lu, Junqin, Bi, Yihui, Zhu, Yapeng, Duan, Wenxiu, Zhou, Jian. 2021. CD3D, GZMK, and KLRB1 Are Potential Markers for Early Diagnosis of Rheumatoid Arthritis, Especially in Anti-Citrullinated Protein Antibody-Negative Patients. In Frontiers in pharmacology, 12, 726529. doi:10.3389/fphar.2021.726529. https://pubmed.ncbi.nlm.nih.gov/34603038/
10. Ma, Dongli, Zhong, Shan, Liu, Xiaorong, Xu, Cheng, Zhou, Fengfeng. 2016. CD3D and PRKCQ work together to discriminate between B-cell and T-cell acute lymphoblastic leukemia. In Computers in biology and medicine, 77, 16-22. doi:10.1016/j.compbiomed.2016.07.004. https://pubmed.ncbi.nlm.nih.gov/27494091/